3
Announcements
Trials
Browse
Landscape
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Non-Muscle Invasive Bladder Neoplasms
15
Urinary Bladder Neoplasms
14
Carcinoma, Transitional Cell
14
Neoplasms
5
Urologic Neoplasms
4
Urologic Diseases
3
Urogenital Neoplasms
3
Urinary Bladder Diseases
3
Neoplasms by Site
3
Carcinoma
3
Recurrence
2
Carcinoma in Situ
2
Virus Diseases
1
Urogenital Diseases
1
Neoplasms by Histologic Type
1
Neoplasm Recurrence, Local
1
Mycobacterium Infections
1
Male Urogenital Diseases
1
Female Urogenital Diseases
1
Disease
1
Carcinoma, Hepatocellular
1
Adenoviridae Infections
1
Interventions
Pemetrexed
5
ponatinib
4
pembrolizumab
4
Carboplatin
4
Cisplatin
3
130-nm albumin-bound paclitaxel
3
tetulomab tetraxetan lu-177
2
pralsetinib
2
osimertinib
2
napabucasin
2
fludarabine
2
ficlatuzumab
2
entinostat
2
durvalumab
2
atezolizumab
2
Rituximab
2
Paclitaxel
2
Lutetium
2
Irinotecan
2
Immunotherapy
2
Imatinib Mesylate
2
Gemcitabine
2
Doxorubicin
2
Dexamethasone
2
Cyclophosphamide
2
Bortezomib
2
Bevacizumab
2
vorasidenib
1
siltuximab
1
ruxolitinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Neoplasms by Histologic Type
×
Mitomycin
×
Clear all
NCT05874921
2025-02-28
uTRACT
UroGen Pharma Ltd.
Recruiting
400 enrolled